Today's diverse companies were chosen for their speculative
enterprises. Both companies deal in the territory of what if. If
Encore Capital Group Inc. (
) can collect more from a huge portfolio of consumer debt, the
company would grow. If Sophiris Bio Inc. (
), a 10-person biopharm, is successful in competing to provide
relief for prostate BPH symptoms, the company would soar.
Sophiris Bio Inc. (
The SPHS share price is currently $4.37 or 85.6% off the 52-week
high of $30.32. Its yield is 0.00%.
Up 2,426% over 12 months, Sophiris Bio Inc. has a market cap of
$75.57 million and entries value of $71.58 million. Shares trade at
a P/S of 2.98. The company is way up from its August IPO.
Formed in 2003, Sophiris Bio Inc. is a clinical-stage
biopharmaceutical company that develops and commercializes products
for the treatment of urological diseases. The company is currently
developing PRX302 for the treatment of benign prostatic
hyperplasia, or BPH, a non-cancerous enlargement of the prostate
The company's product "PRX302" is a recombinant form of a protein
that is highly targeted to prostate tissue. According to the
company, the protein is smart: "Once activated, PRX302 forms
disruptive pores in the membranes of prostate cells resulting in
selective cell death, thus creating a highly targeted, localized
approach to killing prostate cells constricting the urethra."
The company reported that it raised $65 million in its August IPO,
selling 13 million shares for $5 per share. Insiders made
four buys of SPHS stock
For the second quarter ended June 30, 2013, the company reported a
net loss of $2.6 million, compared to a net loss of $5.7 million
for the same period in 2012. The earnings per share for the most
recent quarter were ($0.02) per share, compared to ($0.03) per
share for the same quarter in 2012. Sophiris Bio spent $1.2 million
in the second quarter of 2013 for research and development, much
less than in the same period a year ago at $3.7 million.
No gurus currently hold shares but there is insider trading.
Tracking share price, revenue and net income:
Encore Capital Group Inc. (
Up 58% over 12 months, Encore Capital Group Inc. has a market cap
of $1.15 billion and an enterprise value of $2.04 billion. Shares
trade with a P/E of 16.10 and a P/B of 2.30.
The ECPG share price is currently $45.59.
Incorporated in 1999, Encore Capital Group Inc. is a debt
management and recovery solutions company, headquartered in San
Diego. Encore Capital Group purchases portfolios of defaulted
consumer receivables at deep discounts to face value and manages
them by partnering with individuals as they repay their obligations
and work towards financial recovery.
In June Encore Capital Group acquired Asset Acceptance Capital
Corporation for around $200 million or $6.50 per share. At the time
of the acquisition announcement, Asset Acceptance had $1 billion in
estimated remaining collections. The acquisition included all
operating subsidiaries of Asset Acceptance. After the acquisition,
Encore has over 60 million individual consumer accounts,
representing a face value of over $130 billion.
The company reported financial results for the second quarter of
2013 with $152 million in revenue, compared to $138.7 million in
the same quarter a year ago. The company's gross collections were
up 16% over last year in the same quarter, at $278.4 million
compared to $240.6 in the second quarter of 2012.
Jim Simons is the sole Guru stakeholder, and there is insider
As of June 30, 2013, long-time stakeholder,
made a new buy of 108,409 shares at an average price of $31.92 for
a gain of 42.8%. Check out his remarkable five-year history showing
solid gains and no losses:
Tracking share price, revenue and net income since 1999:
Check out the GuruFocus special feature
52-week low screener
to find the stocks hitting new lows but are still held by top
investor Gurus and Insiders.
Try a Premium Membership
7-day Free Trial
About GuruFocus: GuruFocus.com tracks the stocks picks and
portfolio holdings of the world's best investors. This value
investing site offers stock screeners and valuation tools. And
publishes daily articles tracking the latest moves of the world's
best investors. GuruFocus also provides promising stock ideas in 3
monthly newsletters sent to